Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...

Q4 2025 Management View CEO Eric Dube stated that "2025 was an incredible year for Travere, one that was defined by achieving ...

Travere (TVTX) delivered earnings and revenue surprises of +16.73% and -8.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of ...

Inc.), , a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address ...

The drug developer posted revenue of $129.7 million in the period, which did not meet Street forecasts. Six analysts surveyed by Zacks expected $142.5 million. For the year, the company reported a ...

Travere Therapeutics (NASDAQ: TVTX) reported its Q4 earnings results on Thursday, February 19, 2026 at 04:01 PM. Here's what investors need to know about the announcement. Travere Therapeutics beat ...

Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Travere Therapeutics Inc reports fourth-quarter earnings Thursday after market close, with investors focused on the rare disease specialist’s commercial momentum following a regulatory setback that ...

Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $0.24. The market awaits Travere ...

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...